NanoSYS Biologics is Company in the early stage, which utilizes its proprietary immune checkpoint(s) and enabling nanoplatform (CheckpointNanotheraIM) for cancer immunotherapy. CheckpointNanotheraIM uses nanoparticles to treat cancer by targeting multiple diverse immune checkpoints in the immune system instead of the tumor itself. This is an attractive approach, since fighting tumor directly requires depletion of all malignant cells. Even a small number of surviving tumor cells can induce recurrence, thus a traditional anticancer drug needs to reach billions of cells. On the contrary for cancer immunotherapy it is more realistic to achieve the activation of several thousands of leukocytes sufficient to induce potent anti-cancer responses.